

Substitute for form 1449A/PTO (Revised 10/2001)				Complete if Known	
				Application Number	09/930,905
				Filing Date	August 16, 2001
				First Named Inventor	Christopher T. Privalle
				Group Art Unit	1653
				Examiner Name	(not yet assigned)
Sheet	1	of	1	Attorney Docket Number	35780/238028 (5780-4)

U. S. PATENT DOCUMENTS					

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Column, Lines, Where Relevant Passages or Relevant Figures Appear
JRC	45	WO 90/15613	12/27/1990	Rorer International	4 Cited/561
JRC	46	EP 0 156 961 A2	10/09/1985	Bioteest Pharma GMBH	—

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
Examiner Signature	Jeffrey Russell			Date Considered	March 4, 2003

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A/PTO
(Revised 10/2001)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet

1

of

3

Complete if Known

Application Number	09/930,905
Filing Date	August 16, 2001
First Named Inventor	Privalle
Group Art Unit	1653
Examiner Name	(not yet assigned)
Attorney Docket Number	35780/238028 (5780-4)

TECH

CENTER

FEB

11

2001

RECEIVED
FEB 11 2001
1600/2380

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Cites / Subless Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
JER	1	US - 4,301,144	11-17-1981	Iwashita <i>et al.</i>	Whole document 514/6
JER	2	US - 4,412,989	11-01-1983	Iwashita <i>et al.</i>	Whole document 530/385
JER	3	US - 4,529,719	07-16-1985	Tye	Whole document 514/6
JER	4	US - 4,670,417	06-02-1987	Iwasaki <i>et al.</i>	Whole document 514/6
JER	5	US - 4,826,811	05-02-1989	Sehgal <i>et al.</i>	Whole document 514/6
JER	6	US - 5,084,558	01-28-1992	Rausch <i>et al.</i>	Whole document 530/385
JER	7	US - 5,194,590	03-16-1993	Sehgal <i>et al.</i>	Whole document 530/385
JER	8	US - 5,217,648	06-08-1993	Beissinger <i>et al.</i>	Whole document 514/6
JER	9	US - 5,234,903	08-10-1993	Nho <i>et al.</i>	Whole document 514/6
JER	10	US - 5,264,555	11-23-1993	Shorr <i>et al.</i>	Whole document 530/385
JER	11	US - 5,281,579	01-25-1994	Estep	Whole document 514/6
JER	12	US - 5,296,465	03-22-1994	Rausch <i>et al.</i>	Whole document 514/6
JER	13	US - 5,312,808	05-17-1994	Shorr <i>et al.</i>	Whole document 514/6
JER	14	US - 5,386,014	01-31-1995	Nho <i>et al.</i>	Whole document 530/385
JER	15	US - 5,439,591	08-08-1995	Pliura <i>et al.</i>	Whole document 530/385
JER	16	US - 5,464,814	11-07-1995	Sehgal <i>et al.</i>	Whole document 514/6
JER	17	US - 5,478,805	12-26-1995	Shorr <i>et al.</i>	Whole document 514/6
JER	18	US - 5,545,328	08-13-1996	Pliura <i>et al.</i>	Whole document 530/385
JER	19	US - 5,606,025	02-25-1997	D'Agnillo <i>et al.</i>	Whole document 530/385
JER	20	US - 5,741,894	04-21-1998	Azari <i>et al.</i>	Whole document 530/385
JER	21	US - 5,840,701	11-24-1998	Hsia	Whole document 514/21
JER	22	US - 5,905,141	05-18-1999	Rausch <i>et al.</i>	Whole document 530/385
JER	23	US - 5,998,361	12-07-1999	Bucci <i>et al.</i>	Whole document 514/2
Examiner Signature	Jeffrey E. Russell			Date Considered	March 4, 2003

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A/PTO
(Revised 10/2001)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	09/930,905
Filing Date	August 16, 2001
First Named Inventor	Privalle
Group Art Unit	1653
Examiner Name	(not yet assigned)
Attorney Docket Number	35780/238028 (5780-4)

RECEIVED
FEB 11 2002
TECH CENTER 1600/2800
FEB 11 2002
1600/2800

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
JER	36 *	LI, H., <i>et al.</i> , "Polynitroxylation Neutralizes the Hypertensive Effect of $\alpha\alpha$ -Crosslinked Hemoglobin without Affecting Nitric Oxide Scavenging," 6 th Annual Meeting of the Oxygen Society, November 18-22, 1999, Abstract No. 234.	
JER	37 *	MAO, G. <i>et al.</i> , "Superoxide Dismutase (SOD)-Catalase Conjugates, <i>Journal of Biological Chemistry</i> , January 1993, pp. 416-420, Vol. 268(1), The American Society for Biochemistry and Molecular Biology, Inc., USA.	
JER	38 *	PRIVALLE, C., <i>et al.</i> , "Pyridoxalated Hemoglobin Polyoxyethylene: A Nitric Oxide Scavenger With Antioxidant Activity For The Treatment Of Nitric Oxide-Induced Shock," <i>Free Radical Biology and Medicine</i> , May 2000, pp. 1507-1517, Vol. 28(10), USA.	
JER	39	PRIVALLE, C., <i>et al.</i> , "Pyridoxalated Hemoglobin-Polyoxyethylene(PHP): A Nitric Oxide Scavenger With Antioxidant Properties," 4 th Annual Meeting of the Oxygen Society, 1997, USA.	
JER	40	PRIVALLE, C., <i>et al.</i> , " Pyridoxalated Hemoglobin Polyoxyethylene (Php) - A Modified Hemoglobin Therapeutic With Sod-Catalase Activity," 6 th Annual Meeting of the Oxygen Society, November 18-22, 1999, Abstract No. 254.	
JER	41 *	QUEBEC, E. and CHANG, T., "Superoxide Dismutase and Catalase Cross-Linked to Polyhemoglobin Reduces Methemoglobin Formation <i>In Vitro</i> ," <i>Art. Cells. Blood Subs., and Immob. Biotech.</i> , 1995, pp.693-705, Vol. 23(6), Marcel Dekker, Inc.	
JER	42	RAZACK S., <i>et al.</i> , "Crosslinked Hemoglobin-Superoxide Dismutase-Catalase Scavenges Free Radicals in a Rat Model of Intestinal Ischemia-reperfusion Injury," 1997, <i>Art. Cells, Blood Subs. and Immob. Biotech.</i> pp. 181-192, Vol. 25(1&2), Marcel Dekker, Inc.	
JER	43 *	SATO, <i>et al.</i> , "Synthesis and Characterization of Superoxide Dismutase-Deferoxamine Conjugate Via Polyoxethylene: A New Molecular Device for Removal of a Variety of Reactive Oxygen Species", <i>Bioconjugate Chem.</i> , 1995, pp. 249-254, Vol. 6(3), American Chemical Society, USA.	
JER	44	TALARICO, T., <i>et al.</i> , "Chemical Characterization of Pyridoxalated Hemoglobin Polyoxyethylene Conjugate," <i>BBA</i> , January 2000, pp. 53-65, Vol. 1476, Elsevier Science, BV.	
Examiner Signature	Jeffrey E. Russell		Date Considered

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

September 24, 2003



Substitute for form 1449A/PTO
(Revised 10/2001)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

Application Number	09/930,905
Filing Date	August 16, 2001
First Named Inventor	Privalle
Group Art Unit	1653
Examiner Name	(not yet assigned)

Attorney Docket Number 35780/238028 (5780-4)

RECEIVED
FEB 11 2003
TECH CENTER 1600/2900

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
JR	24	AZARI, M., et al., "Diaspirin Crosslinked Hemoglobin (DCLHb™): Characterization of the Process and the Product Manufactured under GMP Requirements for Clinical Studies," <i>Art. Cells, Blood Subs., and Immob. Biotech.</i> , 1994, pp. 701-708, Vol. 22(3).	
JR	25	BECHTEL, M., et al., "Virus Removal or Inactivation in Hemoglobin Solutions by Ultrafiltration or Detergent/Solvent Treatment," <i>Biomater. Artif. Cells Artif. Organs</i> , 1988, pp. 123-128, Vol. 16(1-3).	
JR	26	BONE, H., et al., "Pyridoxalated Hemoglobin Polyoxethylene Conjugate Reverses Hyperdynamic Circulation in Septic Sheep," <i>J. Appl Physiol.</i> , 1998, pp. 1991-1999, Vol. 84, American Physiological Society, USA.	
JR	27	CHANG, T., "Future Prospects for Artificial Blood", <i>TIBTECH</i> , February 1999, pp. 61-67, Vol. 17(2), Elsevier Trends Journals, UK.	
JR	28	D'AGNILLO, F. and CHANG, T., "Polyhemoglobin-Superoxide Dismutase-Catalase as a Blood Substitute with Antioxidant Properties," <i>Nature Biotechnology</i> , 1998, pp. 667-671, Vol. 16.	
JR	29	D'AGNILLO, F. and CHANG, T. "Reduction of Hydroxyl Radical Generation in a Rat Hindlimb Model of Ischemia-Reperfusion Injury Using Crosslinked Hemoglobin-Superoxide Dismutase-Catalase," 1997, <i>Art. Cells, Blood Subs. and Immob. Biotech.</i> , 1997, pp. 163-180, Vol. 25, Marcel Dekker, Inc.	
JR	30	D'AGNILLO, F. and CHANG, T., "Cross-Linked Hemoglobin-Superoxide Dismutase-Catalase Scavenges Oxygen-Derived Free Radicals and Prevents Methemoglobin Formation and Iron Release," 1993, <i>Biomat., Art. Cells, & Immob. Biotech.</i> , 1993, pp. 609-621, Vol. 21(5), Marcel Dekker, Inc.	
JR	31	D'AGNILLO, F. and CHANG, T., "Crosslinked Hemoglobin-Superoxide Dismutase-Catalase Reduces Hemoprotein-Associated Free Radical Events in Models of <i>In Vitro</i> and <i>In Vivo</i> Oxidative Stress," <i>Abstracts from the VI International Symposium on Blood Substitutes</i> , 1996, Vol. 24(4), p. 327.	
JR	32	ESTEP, T., et al., "The Purification of Hemoglobin Solutions by Heating," <i>The Red Cell: Seventh Ann Arbor Conference</i> , 1989, pp. 325-338, Alan R. Liss, Inc.	
JR	33	FARMER, M., et al., "Validation of Virus Inactivation by Heat Treatment in the Manufacture of Diaspirin Crosslinked Hemoglobin," 1992, <i>Biomater. Artif. Cells Immobilization Biotechnol.</i> , pp. 429-433, Vol. 20.	
JR	34	HIGHSIMITH, F., et al., "An Improved Process for the Production of Sterile Modified Haemoglobin Solutions," <i>Biologicals</i> , 1997, pp. 1-12, Vol. 25, The International Association of Biological Standardization, USA.	
JR	35	IWASHITA, Y., "Hemoglobin Conjugated with Polyoxethylene", <i>Artificial Red Cells</i> , 1995, pp. 151-176, John Wiley and Sons Ltd.	
Examiner Signature	<u>Jeffrey E. Russell</u>		Date Considered <u>March 4, 2003</u>

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

September 15, 2003